** Shares of drug developer Mersana Therapeutics MRSN.O rise 5.38% to $1.38 premarket
** Co says U.S. FDA has granted additional fast track tag to its experimental drug XMT-1660
** The new tag is for the treatment of some patients with a type of breast cancer
** The FDA's Fast Track program is designed to facilitate the development and expedite the review of drug candidates to treat serious conditions and fill an unmet medical need
** Separately, co announced data from an early-stage trial of the drug in patients with a type of breast cancer
** Stock fell 38.36% last year
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.